Vijay R. Nadipelli - Concepedia

Author

Vijay R. Nadipelli

Also Known As

V Nadipelli, V. Nadipelli, V.R. Nadipelli, VR Nadipelli, Vijay Nadipelli, Vijay R Nadipelli, Vijay R. Nadipelli, Vijay R. Nadipelli, BPharm, MS

Publications

844

Citations

H-Index

Concepts

All Affiliations

Indivior (United States)Pharmerit (United States)RTI International Artemis (United States)Aventura Hospital and Medical Center

About

Vijay R. Nadipelli is an author at Indivior (United States) specializing in medicine, psychiatry, and opioid use disorder.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	311
2	Psychiatry	3	3	311
3	Health Sciences	2	2	287
4	Public Health	1	1	19
5	Health Policy	1	1	19

Vijay R. Nadipelli

Publications

804

Citations

H-Index

Page 1

	Year	Citations
Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Barbara R. Haight, Susan M. Learned, Céline M. Laffont, The Lancet Opioid EpidemicSubstance UsePsychiatryPain MedicineAddiction	2019	268
Relationship between buprenorphine adherence and relapse, health care utilization and costs in privately and publicly insured patients with opioid use disorder Naoko Ronquest, Tina M. Willson, Leslie Montejano, Substance Abuse and Rehabilitation	2018	100
Factors associated with opioid overdose: a 10-year retrospective study of patients in a large integrated health care system Joseph A. Boscarino, H. Lester Kirchner, James Pitcavage, Substance Abuse and Rehabilitation	2016	65
Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: A long-term study Walter Ling, Vijay R. Nadipelli, Caitlyn T. Solem, Journal of Substance Abuse Treatment	2019	54
Recovery From Opioid Use Disorder (OUD) After Monthly Long-acting Buprenorphine Treatment: 12-Month Longitudinal Outcomes From RECOVER, an Observational Study Walter Ling, Vijay R. Nadipelli, Arnie Aldridge, Journal of Addiction Medicine	2020	52
Patient-centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study Walter Ling, Vijay R. Nadipelli, Caitlyn T. Solem, Journal of Addiction Medicine	2019	44
Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis Anne C. Andorn, Barbara R. Haight, Sunita Shinde, Journal of Clinical Psychopharmacology	2020	43
Heterogeneity of nonadherent buprenorphine patients: subgroup characteristics and outcomes. Charles Ruetsch, Joseph Tkacz, Vijay R. Nadipelli, PubMed	2017	26
Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: An 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study John J. Isitt, Vijay R. Nadipelli, Alex Kouassi, Schizophrenia Research Acute Schizophrenia PatientsMonthly RisperidonePsychiatryHealth-related QualityPsychotropic Medication	2016	24
Characteristics and treatment patterns of US commercially insured and Medicaid patients with opioid dependence or abuse Bernd Wollschlaeger, Tina M. Willson, Leslie Montejano, Journal of Opioid Management	2017	23

Page 1